Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06420700 · ClinicalTrials.gov registry record
Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)
A clinical trial of Obesity, sponsored by True You Weight Loss.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT06420700: Recruiting study of Obesity, sponsored by True You Weight Loss.
NCT06420700 is a study of Obesity that is actively recruiting participants, run by True You Weight Loss. The registered enrollment target is 100 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06420700, a study of Obesity, is actively recruiting participants, sponsored by True You Weight Loss.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone combined gastric mucosal ablation with endoscopic sleeve gastroplasty at True You Weight Loss.
Primary Outcome
Measured percent change in total body weight over time following combined Gastric Mucosal Ablation. %TBWL = (pre-op weight - post op body weight) / (pre-op weight) \* 100 measured as a percentage.
Conditions Studied
Interventions
- PROCEDURE Combined gastric mucosal ablation with endoscopic sleeve gastroplasty
Study Locations (2)
Georgia
- True You Weight Loss - Atlanta
North Carolina
- True You Weight Loss - Cary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2028-01-31 |
What NCT06420700 shows while recruiting
NCT06420700 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Combined gastric mucosal ablation with endoscopic sleeve gastroplasty is the first listed.
NCT06420700 reports a single indexed study location in Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06420700 about?
NCT06420700 is a clinical study titled "Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)". The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone combined gastric mucosal ablation with endoscopic sleeve gastroplasty at True You Weight Loss.
What is the current status of trial NCT06420700?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-01-31. Estimated completion is 2028-01-31.
What conditions does trial NCT06420700 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06420700?
The interventions under investigation include: Combined gastric mucosal ablation with endoscopic sleeve gastroplasty (PROCEDURE).
Who is sponsoring clinical trial NCT06420700?
This trial is sponsored by True You Weight Loss, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06420700 being conducted?
This trial has 2 study locations across Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06420700's enrollment target sits among peer trials
100 478th of 1053 higher than 555 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI